Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity

摘要

Abstract Oral paclitaxel (PTXL) formulations freed from cremophor ? EL (CrEL) is always in utmost demand by the cancerous patients due to toxicities associated with the currently marketed formulation. In our previous investigation [ Int. J. Pharm. 2014; 460:131], we have developed an oral oil based nanocarrier for the lipophilic drug, PTXL to target bioavailability issue and patient compliance. Here, we report in vivo antitumor activity and 28-day sub-chronic toxicity of the developed PTXL nanoemulsion. It was observed that the apoptotic potential of oral PTXL nanoemulsion significantly inhibited the growth of solid tumor (59.2?±?7.17%; p ? ? ) was found to be comparatively more toxic to the experimental animals. Taxol ? treatment resulted glomerulonephritis in histopathological examination, which could be correlated with increased level of creatinine and associated nephrotoxicity. This investigations conclude that the developed oral nanoemulsion presents a viable therapeutics bio-system to step towards clinical application as well as substitute CrEL based PTXL formulations. Graphical abstract Display Omitted Highlights ? Pronounced in vivo antitumor efficacy of oral paclitaxel nanoemulsion in solid tumor bearing model. ? The 28-day toxicity study of the nanoemulsion proved to be a viable media to deliver paclitaxel. ? Overall, devoid of Cremophor ? EL in paclitaxel formulation has proved its safety against nephrotoxicity. ? The developed nanosystem pose higher potential to step towards its clinical application.